Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for reversal of rocuronium block in high-risk elderly surgical patients
ACTRN12614000108617Phase 4Recruiting
- Sponsor
- Thomas Ledowski
- Start
- May 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 4
01
Overview
Phase 4, randomised, single-blind trial of Sugammadex, neostigmine, rocuronium and atropine in neuromuscular block (NMB) (2 arms), sponsored by Thomas Ledowski. Primary endpoint: Pulmonary outcome score. Started May 2014; status: recruiting.
02
Drugs
Sugammadexneostigminerocuroniumatropine
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on ACTRN12614000108617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000108617.